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Cell cycle arrest, senescence and apoptosis are commonly regarded as the major tumor suppression mechanisms of
p53. However, accumulating evidence indicates that loss of these canonical functions is not sufficient for tumor
formation, highlighting the complexity of p53-mediated tumor suppression. PCDH10 belongs to a proto cadherin
protein family and is a potential tumor suppressor protein as the dysregulation of PCDH10 gene frequently existed in
multiple human tumors. Here, we found that PCDH10 is a transcriptional target of p53 and that the levels of PCDH10
expression can be induced by wild type p53 but not mutant p53 in a number of human cancer cell lines. Moreover, we
identified a p53 consensus binding site located in the PCDH10 promoter region that is responsive to p53 regulation.
Although upregulation of PCDH10 has no obvious effect on growth arrest or apoptosis in human cells, PCDH10 exhibits
inhibitory roles in cancer cell motility and cell migration. These results suggest an important role of p53 in regulating
tumor cell migration through activating PCDH10 expression and support the notion that non-canonical activities of p53
may contribute to its tumor suppressor function in vivo.
Introduction
The tumor suppressive function of p53 has never been con-
tested and the “three major classic” functions of p53, cell-cycle
arrest, apoptosis, and senescence, have been ascribed to the pri-
mary actions of p53 in tumor prevention.6 However, an unantici-
pated and possibly intriguing work challenged this dogma by
showing tumor free mice which carried p53 mutations leading to
the disruption of all 3 fundamental functions of p53.8 Certainly
this work implied that the molecular mechanism of p53-medi-
ated tumor suppression is far beyond being understood fully; this
work as well generated the motivation to reexamine the p53 non-
canonical functions that have been proposed from numerous for-
mer studies and to carefully re-analyze the p53 transcriptional
program, for identifying novel targets, which may contribute as
critical components to the tumor suppressive role of p53. In fact,
a growing number of non-canonical p53 target genes have been
added to the p53 transcription program, and these genes encode
for proteins ranging over a broad spectrum of cellular functions
in cell metabolism, stem cell differentiation, tumor cell invasion,
and yet unknown functions.1
The aberrantly increased tumor cell mobility contributes to
tumor invasiveness and metastasis potential, which account for
the most of the resultant mortality of cancer patients.15,17 This
has not escaped the attention of p53 and the accumulating evi-
dence recently linked p53 to key stages of metastatic progression,
including cell adhesion, cell migration and cell invasion.17 It has
been observed for long time that the deletion of p53 allows
fibroblast to migrate faster in wound healing assays, potentially
due to the altered cell morphology and polarity.14,21 This obser-
vation is not only limited to fibroblast, but also expanded to mul-
tiple cancer epithelial cell lines.14,21 However, the underlying
molecular mechanism of this regulation is, at least partially, kept
unknown and requires delineated studies. It was discovered that
the loss of p53 activates Rho signaling pathway, a well-established
pathway to influence the way in which tumor cells migrate, to
promote cell migration.4 In addition, p53 also induces the degra-
dation of slug, a key transcript factor in regulating epithelial-mes-
enchymal transition (EMT), to suppress tumor cell invasion.17,26
Further, tumor derived mutant p53 enhances integrin and epi-
dermal growth factor receptor (EGFR) trafficking therefore pro-
motes cell migration and invasion.14,16 Numerous proteins have
been linked to the p53’s ability in controlling cell migration and
metastasis, such as Rho GTPases (Cdc42,RhoE,Caldesmon),
EMC(extra cellular matrix)protein MMP-2, growth factor
EGFR, and PTEN etc.; however, most of these mediators of p53
in regulating cell migration and metastasis are repressed targets of
p53, secondary transcriptional targets of p53, or regulated mole-
cules by p53 in a transcriptional-independent manner.14 The
direct transcriptional targets of p53 that functions as cell migra-
tion and invasion regulators are scarce. In this study, we report
that Protocadherin 10(PCDH10) is a direct p53 transcriptional
target and regulate tumor cell motility and further cell migration.
PCDH10 is a protocadherin protein and protocadherins are a
group of transmembrane proteins that belong to the cadherin
superfamily.24 PCDH10 contains 6 cadherin domains and one
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transmembrane region in the carboxyl-terminus (Fig. 1A).7
PCDH10 has been proved essential for neuronal development.24
Moreover, PCDH10 is designated as an autism-spectrum disor-
der gene.23 Recently, the strong link has been built between
PCDH10 gene and tumor development. PCDH10 inactivation
through genetic deletion or promoter methylation has been pre-
sented in multi-kind of human cancers including colon cancer,
gastric cancer, prostate cancer and lymphoid malignancies
etc.10–12,18–20,30 Moreover, that the methylation level of
PCDH10 correlates with clinical parameters manifests the signif-
icance of PCDH10 in the tumor progression process.29 For
example, methylation status of PCDH10 is associated with poor
prognosis in patients with bladder cancer.12 Similarly, downregu-
lation of PCDH10 expression correlates with malignant behavior
Figure 1. PCDH10 is induced by p53 in B cell lymphoma cells. (A) Diagram of PCDH10 proto cadherin protein. The pink oval represents for cadherin (CA)
domain and the yellow rectangular represents for the transmembrane domain. (B) The expression level of PCDH10 and p21 in DOHH2, SUDHL4 and
SUDHL5 B cell lymphoma cells. Cells were treated with 10 mM Nutlin-3A for 0, 16 and 24 hours and total RNA were extracted, and cDNA was prepared
by reverse transcription. mRNA abundance for PCDH10 and p21 was assessed using quantitative real time PCR. The western blot analysis of PCDH10 pro-
tein expression was done at indicated time points.
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and poor prognosis in human bladder cancer.13 PCDH10 down-
regulation is widely involved into many types of cancers, suggest-
ing PCDH10 as a potential novel tumor suppressor. The cellular
functions of PCDH10 have been reported highly diversified and
probably differential in tissue specific manner. The re-expression
of PCDH10 could induce cell cycle arrest, apoptosis, and inhibit
cell clonogenicity, though with underlying working mechanism
undiscovered; however these proposed functions substantiate the
tumor suppressive role of PCDH10.19,20,28,29 The basic tran-
scriptional regulatory mechanism of PCDH10 gene is absent
from the previous studies except for the profound epigenetic
studies from tumor samples.
In this study, we find that p53 is a bona find transcription fac-
tor of PCDH10 gene and serves as a generic transcription regula-
tory factor in tested multiple tumor cell lines. The exogenous
overexpression of PCDH10 does not induce significant apoptosis
or cell growth arrest. Instead, PCDH10 performed non-canoni-
cal function of p53. We report here that PCDH10 restrains can-
cer cell migration in non-small cell lung cancer cells, potentially
contributing to the tumor suppressive function of p53.
Results
PCDH10 is induced by p53 in B-cell lymphoma cells
The linkage between p53 and PCDH10 was firstly built up
through a RNA sequencing screening project performed in
H1299 non-small cell lung cancer cells with mouse p53 exoge-
nously overexpressed. PCDH10 mRNA level was up-regulated at
multiple time points upon p53 overexpression, therefore
PCDH10 gene was suspected as a p53 inducible gene. To con-
firm that PCDH10 is a truly p53-inducible gene, we examine
PCDH10 expression level in B-cell lymphoma cell lines, in which
p53 gene alterations are relatively rare, in response to p53 activa-
tion. In DOHH2 B-cell lymphoma cells containing endogenous
wild type p53, the expression level of p21, a classic p53 target
gene, was stimulated by multi-tenfold upon p53 activation when
cells were incubated with 10 uM Nutlin-3a for 16 and 24 hours
(Fig. 1B). PCDH10, probably as a weak p53 induced gene tar-
get, has been observed with 1.5 and 2.5 times of induction at the
similar time points (Fig. 1B). Similarly, PCDH10 mRNA level
increased in a time-dependent manner, as well as other p53 gene
target p21 in SUDHL5 wild type p53 containing B-cell lym-
phoma cell line with Nutlin-3a treatment (Fig. 1B). In contrast,
PCDH10 expression level remains at the basal level in mutant
p53 containing SUDHL4 lymphoma cells under the similar
treatment of p53 activating reagent (Fig. 1B). Similar to
PCDH10 mRNA, the protein levels of PCDH10 were aug-
mented upon Nutlin-3A treatment in DOHH2 and SUDHL5
cells but not in SUDHL4 cells (Fig. 1B).
PCDH10 is induced by p53
The previous data showed that the activation of endogenous
p53 could induce PCDH10 gene expression. We next explore if
PCDH10 gene induction will recapitulate when p53 is exoge-
nously expressed. The induction fold of PCDH10 gene upon
p53 activation in lymphoma cells in nature is modest. To mimic
physiological condition and maintain sustained p53 activation
for extended time period, we established an inducible cell line
expressing tetracycline regulated wild-type mouse p53 in ptripz
vector. These cells express relatively low level of p53 upon addi-
tion of tetracycline in short time period and p53 activation could
continue for days without inducing apoptosis for cell to demise
until late time point. Therefore, the activation of p53’s “weak,"
or low DNA-binding targets could be amplified more than that
under transient p53 overexpression condition. As expected,
enforced wild-type p53 expression activates p21 for hundreds of
fold when p53 expression was induced by addition of 0.5 ug/ml
tetracycline for 16 hour, 24 hour and 48 hours (data not
shown). At same indicated time point, PCDH10 mRNA was
induced to 15, 20, and 22 folds, demonstrating a dramatic activa-
tion by p53 (Fig. 2A). As PCDH10 gene showed quite abundant
basal level in H1299 cells, we performed western blot analysis in
H1299 cells with p53 induction. Similar to PCDH10 mRNA,
PCDH10 protein level increased in a p53 dose-dependent man-
ner along with other classic p53 target genes, including p21,
PUMA and MDM2(Fig. 2B).
To confirm whether PCDH10 induction by p53 is limited to
certain cell type or not, we examined PCDH10 mRNA expres-
sion in response to p53 activation in other types of cancer cell
lines containing wild type p53. PCDH10 has been reported to
be silenced by promoter methylation to differential extent in
multiple human cancers. Therefore PCDH10 induction upon
p53 activation is not expected entirely universal. For example,
HepG2 (Human hepatocellular carcinoma) cells have been tested
for PCDH10 transcripts by real time PCR and PCDH10
mRNA was undetectable probably due to hypermethyletion sta-
tus of its promoter region. In lung cancer cell line H460 and mel-
anoma cell line wm2664, both of which bear wild type p53,
PCDH10 mRNA levels were measured by real-time PCR and
exhibited measurable quantity. In both cell lines, PCDH10
mRNA level were induced at multiple time points when cells
were treated with 1 uM doxorubicin for 12, 24 and 36 hours for
p53 activation (Fig. 2D, E). In contrast, in AU48 renal carci-
noma cells and A375 melanoma cells, PCDH10 expression failed
to show even slight induction in response to p53 activation (data
not shown). Collectively, p53 activates PCDH10 gene expression
in a cell line or tissue dependent manner. To explore if the regu-
lation of PCDH10 expression by p53 is limited to cancer cell
lines, we treated wild type and p53 knockout MEFs with 1 uM
doxorubicin for 12 hours and examined PCDH10 mRNA level.
Although only 2-fold induction of PCDH10 was observed in
p53 wild type MEF upon stress, the silent induction of
PCDH10 in p53 null MEF cells demonstrated that PCDH10 is
modulated by p53 in normal fibroblast cells (Fig. 2C). Collec-
tively, our data indicated that PCDH10 is a novel induced gene
target of p53.
PCDH10 is a transcriptional target of p53
In turn, we investigate if p53 directly regulates PCDH10 gene
expression as its transcriptional factor. 3000 base pair genomic
DNA sequence upstream of transcription start site (TSS) site of
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PCDH10 gene was carefully examined for p53 binding sites (p53
BS) and 4 potential p53 BSs were identified and their locations
were illustrated in Figure 3A. To verify the binding of p53 pro-
tein to the PCDH10 promoter, we performed chromatin-immu-
noprecipitation (CHIP) assay in H1299 cells transfected with
wild type or mutant p53 expression vectors, followed by quanti-
tative real-time PCR (qPCR) amplification of the pulled-down
DNA fragments. The relative wild type p53 enrichment, but not
mutant p53 (R175H) enrichment, was detected at one of the
p53 potential BSs, p53 BS-3, 1.2 kb upstream of TSS, while no
enrichment was detected at the other 3 potential p53 BS, provid-
ing that p53 indeed binds to the PCDH10 promoter (Fig. 3B).
To validate the binding specificity of p53 protein to the iden-
tified PCDH10 promoter region, we next performed gel mobility
shift assay to determine if p53 is able to bind to the PCDH10
promoter region containing p53 BS-3 in this reconstituted in
Figure 2. p53 induces PCDH10 expression. (A) PCDH10 mRNA expression in tet-on-p53 H1299 cells. Tet-on-p53 H1299 cells were induced by addition of
0.5 ug/ml tetracycline (Tet) for 0, 16, 24, and 48 hours. Total RNA were extracted, and cDNA was prepared by reverse transcription. mRNA abundance for
PCDH10 was assessed using quantitative real time PCR. (B) Tet-on-p53 H1299 cells were induced by 0.5 ug/ml tetracycline(tet) at the indicated time point
and the total cell extracts were analyzed by Western blotting using antibodies against p53(CM5), PCDH10, Mdm2, Puma, p21, and b-actin. (C) PCDH10
expression level in MEF cells. PCDH10 mRNA levels were analyzed in p53C/C and p53¡/- MEFs either left untreated or treated with 1 mM Dox (doxorubi-
cin) for 12 hours via RT-PCR. (D,E) The expression level of PCDH10 in H460 and wm2664 cells. H460 and wm2664 cells were treated with doxorubicin at
1 uM for 0, 12 , 24, and 36 hours. Total RNA were extracted, and cDNA was prepared by reverse transcription. mRNA abundance for PCDH10 was assessed
using quantitative real time PCR.
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vitro system, as compared to CHIP assay in whole cell crude mix-
ture. We amplified a 170 bp DNA fragment, covering p53 BS-3
and locating 1200 bp upstream from TSS, from genomic DNA.
Using Flag/M2 immunopurified human p53 protein, we
observed a super shift of this specific PCDH10 promoter frag-
ment (Fig. 3C). In addition, binding of p53 to the radiolabled
PCDH10 fragment was outcompeted by the excessive amount
(100£) of addition of same cold probe (Fig. 3C). Taken
together, these results indicate that PCDH10 gene is a p53 target
and the consensus p53 binding site, p53 BS-3, is responsible for
PCDH10 gene activation.
Since p53 is a transcription factor, we tested whether p53 was
able to activate transcription through the PCDH10 promoter
using luciferase assay. Luciferase constructs pLuc-PCDH10, con-
taining the verified p53 binding site p53 BS-3 and flanking over
600 base pair nucleotides in PCDH10 promoter region, was gen-
erated as illustrated in Fig. 3A (lower panel). Co-transfection of
pLucPCDH10 with wild type p53 expression plasmid into p53
null SAOS2 cells increased the luciferase activity in a p53 dosage
dependent manner (Fig. 3D). In contrast, the co-transfection of
mutant p53 R175H, which is defective in DNA binding, failed
to do so (Fig. 3D). Similar stimulated luciferase activity by wild
type p53 was also observed in H1299 cells. This result demon-
strated that p53 activated gene expression of PCDH10 through
the promoter region as well as confirmed that the potential p53
binding site is in the predicted region, p53 BS-3, of PCDH10
promoter region.
PCDH10 does not convey the classic functions of p53
The dysregulation of PCDH10 gene in multiple tumor sam-
ples and cell lines implied that it might play a suppressive role in
tumorigenesis. As a potential p53 target, we are interested in
exploring whether PCDH10 plays any role in the p53 mediated
canonical cellular functions, such as cell growth arrest and
Figure 3. PCDH10 is a transcriptional target of p53. (A,B) ChIP analysis of p53 enrichment at the promoter region of PCDH10. (A) Upper panel: the sche-
matic representation of human PCDH10 gene and its promoter. The four potential p53 binding sites (p53 BS) are located at 520 bp, 1200 bp, 1800 bp,
2200 bp upstream of TSS (transcription start site) of PCDH10 gene. Lower panel: the schematic representation of luciferase construct pLucPCDH10 con-
taining the potential p53 binding site p53 BS3. (B) ChIP-qPCR analysis of p53 enrichment at the 4 potential binding sites in the promoter regions of
PCDH10 in H1299 cells expressing wild type p53 and R175H mutant p53 protein. (C) Gel shift assay shows p53 binding on oligonucleotide containing
p53-binding site p53 BS-3 in the PCDH10 promoter region. The DNA binding activity of purified p53 protein presents in the radiolabeled PCDH10 probe
and p53 protein complex. Specificity of the binding was confirmed by competition with non-radiolabeled PCDH10 mRNA levels. (D) p53 activates lucifer-
ase activity of reporter construct containing p53 BS-3 in PCDH10 promoter. SAOS2 cells were transfected with 500 ng PCIN4 empty vector (EV), titrated
increasing amounts(100 ng, 200 ng, 500 ng) of PCIN4-WTp53 expression vector, or 500 ng PCIN4-R175H p53 mutant vector along with luciferase con-
struct pLucPCDH10 for 24 hours before measuring luciferase activity by luciferase reporter gene assays (Promega, Dual-Luciferase Assays).
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apoptosis. In support of its prospective tumor suppressive role,
PCDH10 has been proposed and demonstrated to induce G1
cell cycle arrest to suppress tumor cell growth in myeloma cells.9
Since p53 is the major cell cycle arrest effector in G1 phase and
the linkage has been built up between p53 and PCDH10 from
the preceding evidence, we next investigated whether PCDH10
virtually inhibited tumor cell growth as a general phenomenon.
To this end, we established a human PCDH10 containing tetra-
cycline-inducible cell line in H1299 cells as illustrated in
Figure 4A. After the treatment of 5 ug/ml tetracycline for
PCDH10 induction, we extracted cell lysates on every day of 4
successive days and lysates were subjected to western blotting
analysis. The sustained and equal protein expression of PCDH10
gene was perceived at each indicated time point (Fig. 4C). From
the cell growth curve, it is fairly apparent that the cell prolifera-
tion of PCDH10 induced H1299 cells showed insignificant dif-
ference in comparison with that of control H1299 cells
(Fig. 4B). In addition, H1299 cells were transiently transfected
with V5-tagged PCDH10 expression vector or empty control
vector and the transfected cells were subjected to FACS analysis
to measure subG1 population at 24 hours or 48 hours post
transfection. Compared to empty vector transfection, PCDH10
overexpression does not exhibit apparent impact on the abun-
dance of subG1 peak at any time point, implying that PCDH10
does not modulate p53 induced apoptosis (Fig. 4D). Together,
PCDH10 expression does not exhibit any impact onto p53 regu-
lated classis cellular functions.
A potential role of p53 in regulating cell migration
PCDH10 belongs to the protocadherin gene family, a sub-
family of the cadherin superfamily, and its role is presumably
involved in the establishment of cell-cell connections and in the
control of cell migrations.7 Using our established PCDH10
inducible H1299 cells, we are able to test the hypothesis that
PCDH10 influences tumor cell migration without the interfer-
ence of lipofectamine induced cell toxicity. As shown in Fig. 5,
PCDH10 induced cells exhibit visibly and measurably slower
migration rate than control cells in a wound healing assay with a
statistical significance, suggesting that PCDH10 potentially plays
an important role in tumor cell mobility and migration. So far,
the functional assays we have exploited pointed out that
PCDH10 potentiate the cell migratory capability, in accordance
with the frequent loss of PCDH10 gene expression in relatively
later stage of tumor progression rather than in initiation step.
Figure 4. PCDH10 does not convey the classic functions of p53. (A) The schematic representation of the construct design of Ptripz human PCDH10 plas-
mid used to make tet-on-PCDH10 H1299 cells. The image is modified from pTripz vector map on GE Dharmacon website. (B and C) Up-regulation of
PCDH10 does not affect cell growth rate. (B) Cell growth rate analysis of control and PCDH10 induced H1299 cells.Tet-on-PCDH10 H1299 cells
were induced or not by addition of 5 ug/ml tetracycline for 4 successive days and cell numbers were counted on each day for 4 d for growth curve.
(C) The western blot analysis of PCDH10 protein expression was done at indicated time points after the addition of tetracycline. (D) Upregulation
of PCDH10 does not induce apoptosis.H1299 cells were transfected with control empty vector (EV) or V5 tag containing PCDNA3 p53 expression
vector( V5-PCDH10). The cells were harvested at 0, 24, and 48 h post transfection, fixed in cold 80% methanol, stained with propidium iodide and sub-
jected to DNA content analysis by flow cytometry. Cells with sub-G1 DNA content were scored as apoptotic cells.
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Discussion
As one of the most prominent tumor suppressors, p53 protein
has non-canonical functions being kept unveiled or not fully
understood. These functions might contribute to the tumor sup-
pressor role of p53 at different tumor developmental stages and
pathological processes. The inhibitory effect of tumor cell migra-
tion, as a novel p53 function, has been demonstrated involved
with tumor’s invasive and metastatic potential. The control of
cell mobility through p53 pathway has been mostly linked to the
acquired function of mutant p53 deficient in transcriptional
activity.16,27 We found that PCDH10, a likely direct target of
wild type p53, suppresses tumor cell migration in non-small cell
lung cancer cells. The data in our study provided evidence that
PCDH10 might link p53 to its function in tumor cell migration.
PCDH10 belongs to the non-clustered protocaderin protein
family, a subtype of cadherin family distinctive from classical
cadherins.7 Protocadherins are believed to possess important
functions such as intracellular signaling and growth control,
in addition to the generic cell-to-cell adhesion activities of cad-
herin family proteins.7 However, the exact functions of most
protocadherins have not been well elucidated.7 PCDH10 appears
to have cell-cell adhesion property and plays roles in neuronal cir-
cuit formation.24 The deficiency in PCDH10 gene has been
linked to neuronal disease such as autism spectrum disorder.23
PCDH10 has 6 cadherin domains, one transmembrane domain,
and one cytoplasmic sequence, suggesting that PCDH10 could
stimulate intracellular signaling.24 PCDH10 protein is widely
expressed but its function in promoting cell death, inhibiting
tumor cell proliferation, and suppressing cell migration seems
dependent on the cellular context and tissue type. In recent years,
the association of PCDH10 with human malignancies has been
proposed. Numerous studies have demonstrated that PCDH10
expression is partially or completely silent through promoter
methylation or homozygous deletion in several human cancer
types, including lymphoid malignancies, colorectal cancer, lung
cancer, bladder cancer, and prostate cancer.2,3,10–12, 20,25,30 In
our study, it appears that the suppressed cell migration is the
most prominent consequence when PCDH10 induction is intro-
duced. The reported cell death and cell cycle arrest are insignifi-
cant effects of PCDH10 overexpression in H1299 lung cancer
cells. The molecular mechanism of how PCDH10 inhibits tumor
Figure 5. PCDH10 inhibits cell migration in wound healing assay. (A) Tet-on-PCDH10 H1299 cells were plated into 6 well plates at 30% confluence. After
24 hours, cells were scraped to create a wound in the middle of each well. Tet-on-PCDH10 H1299 cells were induced or not by addition of 5 ug/ml tetra-
cycline for 48 hours and 2 pictures (#1,#2) were taken and presented at both 0 hour and 48 hours. (B) Wound gaps were measured using Photoshop
software from pictures taken under 10£ microscopic field. Three measurements were obtained for each sample to calculate mean gap distance. Error
bars indicate §1 standard deviation. (C) PCDH10 expression level in Tet-on-PCDH10 H1299 cells, treated or not by tetracycline, was evaluated in Western
blot analysis at indicated time points.
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cell migration has been suggested to associate with Wnt/b-cate-
nin signaling pathway, however, it is beyond fully understood
and requires delineated studies.29
p53 mediated activation of PCDH10 is limited to certain cell
types, indicating that the transcriptional regulatory machinery of
PCDH10 functions in probably multi-module manner. The
understanding of how PCDH10 is regulated at transcriptional
level stays in the infancy stage and requires future studies. Inter-
estingly, a long-non-coding RNA HOTAIR, whose aberrantly
increased expression frequently shown up in breast cancer metas-
tases, repressed PCDH10 gene expression.5 The interaction
between PCDH10 and other cancer genes are yet to be discov-
ered and the advanced knowledge will help to understand the
role of PCDH10 in tumor pathogenesis. Of note, other proteins
in cadherin protein family have also been reported as candidate
tumor suppressor in human cancers such as prostate cancer and
esophageal carcinoma.2 Among these proposed tumor suppressor
cadherin proteins, E-cadherin (CDH1), like PCDH10, is posi-
tively regulated by p53 at transcriptional level.22 Hypothetically,
p53 may directly and indirectly modulate various cadherin pro-
teins to interfere with cell mobility and further tumor metastasis.
Obviously, it is not reasonable to attribute entire function of p53
in controlling cell migration to any one of its targets. Instead, the
direct and indirect p53 targets in regulating cancer cell migration
and invasion likely form nodes of a multi-component molecular
network to control this particular function of p53.
Accumulating evidence suggests that p53 has broader roles in
tumor suppression than previously thought. It is well established
that p53 responds to oncogenic insult, DNA damage stress, and
other challenging conditions such as metabolic stress and epithe-
lial-mesenchymal transition (EMT) process. It is interesting to
see how p53 programs to coordinately control diverse genes in
various cellular functions and how p53 determines when to elicit
individual gene at different tumor developmental stages to pre-
vent tumorigenesis.
Materials and Methods
RNA Isolation and qRT-PCR
Total RNA was isolated from cells using TRIzol (Invitrogen).
One mg of total RNA was reverse-transcribed using SuperScript
III First-Strand Synthesis SuperMix (Invitrogen) following man-
ufacturer’s protocol. PCR was performed in triplicate using
SYBR green mix (Applied Biosystems), and a 7500 Fast Real-
Time PCR System (Applied Biosystems) under the following
conditions: 15 min at 95C followed by 40 cycles of 95C for
15 s and 60C for 1 min. Primers used for qRT-PCR were listed
as follows, human p21 forward 50- CCATGTGGACCTGT-
CACTGTCTT-30 human p21 reverse 50- cggcCTCTTGGA-
GAAGATCAGCcG-30; human PCDH10 forward
50- AGGCCCTTCACAGCACTCT-30 human PCDH10
reverse 50- AGCATATCCTTTTCCGTG; human PCDH10
(total transcripts) forward 50-GAAGGAGTCTTTTCC-
CAGCTTCA-30 human PCDH10 (total transcripts) reverse 50-
AGACCCAGATCTTCAGCGATA-30; mouse PCDH10
forward 50- CAAGAGAAGGCCCTGCAT-30 mouse PCDH10
reverse 50-AGCTGCATCCACAGCATTT-30
Western Blot Analysis
For Western blot analysis, cells were lysed in cold FLAG lysis
buffer [50 mM Tris¢HCl (pH 7.9), 137 mM NaCl, 10 mM
NaF, 1 mM EDTA, 1% Triton X-100, 0.2% Sarkosyl, 10%
glycerol, and freshly supplemented protease inhibitor(Roche)].
Antibodies used for Western blot analysis are p21 (C-19 and
SX118), and PUMA (H-136) from Santa Cruz, b-actin (AC-
15), and Flag(M2) from Sigma, Vinculin (ab18058) from
Abcam,p53(CM5) from Novusbio, Mdm2 (Ab-5) from EMD
Biosciences, V5 from Invitrogen and PCDH10 (PA5–31042)
from Thermo Scientific.
Plasmids
The full-length PCDH10 cDNA was amplified by PCR from
Human MGC Verified FL cDNA (Open Biosystems) and subcl-
oned into pCDNA3.1 V5-his vector (Invitrogen) and self-modi-
fied pTripZ includible vector (Dharmacon).
Cell culture
SUDHL4, SUDHL5 and DOHH2 cells were maintained in
IMDM (Iscove’s modified Dulbecco’ s medium, Gibco). H1299,
SAOS2, WM2664, H460 and MEF cells were maintained in
DMEM (Cellgro) medium (Cellgro). All media were supple-
mented with 10% fetal bovine serum (Gibco). Transfections
with plasmid DNA were performed by Lipofectamine2000 (Invi-
trogen) according to the manufacturer’s protocol.
Luciferase activity assay Promoter-containing fragments were
amplified from human genomic DNA of H1299 cells and cloned
into the pGL3 luciferase reporter vector using KpnI and Xhol
restriction digest enzyme cutting sites. pLucPCDH10
containing the p53 BS site 3was amplified using forward primer
50 – CGGGGTACCACTATCACGCCCATGGACAC – 30 and
reverse primer 50 – CCGCTCGAGTTTCTGCCAATCCTGG
GGTC – 30. Transfection of SAOS2 cells were performed in 24-
well plate using 0.2 mg luciferase reporter constructs, 0.05 mg
pRL-tk Renilla construct and various amounts of mediated p53
plasmid. Luciferase activities were measured 24 h post-transfec-
tion using Dual-Luciferase Reporter Assay System (Promega).
Firefly luciferase activities were normalized with Renilla luciferase
activities to obtain the relative luciferase activity.
Gel shift assay
Flag-p53 protein was purified from the transfected 293 cells.
The protein-DNA binding reactions (20 ml) contained 20 mM
HEPES (pH 7.6), 80 mM NaCl, 0.1 mM EDTA, 12.5% glyc-
erol, 2 mM MgCl2, 2 mM spermidine, 0.7 mM DTT, 200 ng/
ml BSA, 20 ng/ml sheared sperm DNA, 10–20 fmol DNA probe,
20 ng Flag-p53. The 170 bp DNA fragment used as probe was
obtained by PCR amplification from the PCDH10 promoter,
labeled by T4 kinase (NEB, M0201S) and purified using the
Bio-Spin 30 columns (Bio-Rad). Primers for probe synthesis: for-
ward primer 50-GTTGGGGCTTACACAGAGCTA-30; reverse
primer 50- ACCACTGATTTCTGCCAATCCT-30.
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Chromatin immunoprecipitation (ChIP)
Cells were incubated in culture media containing 1% formal-
dehyde with gentle shaking for 10 min at room temperature, and
crosslinking was stopped by addition of 2.5 M glycine to a final
concentration of 0.125 M glycine. After two washes with cold
PBS, cells were harvested in ice cold lysis buffer (10 mM Tris-Cl
[pH 8.0], 85 mM KCl, 0.5% NP-40, 5 mM EDTA, and fresh
proteinase inhibitor cocktail) and incubated on ice for 10 min.
Nuclei were collected, suspended in cold RIPA buffer (10 mM
Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.1% DOC, 1%
Triton X-100, 5 mM EDTA), and sonicated to shear the geno-
mic DNA to an average of 100–500 bp. Cleared extracts were
precleared with protein A/G beads (Upstate Biotechnology), and
the supernatants were used for immunoprecipitation by p53
FL393(Santa Cruz Biotech) antibody. After five times of wash by
RIPA buffer with gentle rotation for 5 min each time, the pro-
teins were eluted from the beads by 0.5 ml elution buffer (0.1 M
NaHCO3 and 1% SDS). The DNA samples were recovered by
phenol extraction and ethanol precipitation after reversal of cross-
linking. The purified DNA was then analyzed either by PCR
within linear amplification range followed by agarose gel electro-
phoresis or by quantitative real-time PCR using Applied Biosys-
tems 7300. Primers used for the p53 ChIP assay:
PCDH10 p53 putative binding site1 forward 50- GAGCTC
TCCAAAGCAAAATTCTCT-30, reverse 50- TCCGCAAACGT
GGGTTACA -30, PCDH10 p53 putative binding site2 forward
50- AACCCTCTTCCCCAGTTTCTG-30, reverse 50- CGCG
CGTGTTTGCATGT-30, PCDH10 p53 putative binding site3
forward 50- CAGGGAGGATGGATGCAAGT-30, reverse 50-
GCACCGCTGCGGGTATC-30, PCDH10 p53 putative bind-
ing site4 forward 50- TTTTAAAATGCCCTGCCAGTCT-30,
reverse 50- CCCACTAATTGGCAAGGGTTAC-30
Cell motility and migration assays
For wound healing assays, equal numbers of cells were plated
at 30% confluence in 6-well plates, and 24 hours after plating,
gently and slowly scratch the cell monolayer with a new 1 ml
pipette tip across the center of the well. The cells were added
with tetracycline and incubated for 48 hours. Captured images
were used to compare and quantitatively evaluate the gap dis-
tance at each time point. Three independent 10£ fields were
measured for each experiment.
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